Header

Header

Header

Oligo Modifications for Cell Delivery & Uptake

Chemical modifications and conjugation strategies that improve cellular uptake, membrane interaction, intracellular trafficking, endosomal escape and functional delivery of DNA, RNA, antisense, siRNA and therapeutic oligonucleotides.

CPPs • TAT • R9 • Penetratin Cholesterol • Fatty Acids • DAG • Ceramide 2′-O-C16/C18 • Tocopherol • Squalene INF7 • GALA • KALA • Cleavable Linkers HPLC/UPLC • LC-MS • CoA

Design Oligos Around the Cell Uptake Barrier

Bio-Synthesis supports cell uptake-focused oligonucleotide modifications for programs where intracellular entry, trafficking or cytosolic availability limits biological activity.

This page focuses specifically on modifications used to improve cellular delivery and uptake, including cell-penetrating peptides, lipid and vitamin conjugates, nucleoside lipidations, glycan and receptor-assisted uptake ligands, endosomal escape peptides, PEG/TEG spacers, cleavable linkers and multivalent scaffolds.

Our team can help evaluate handle chemistry, conjugation site, linker length, hydrophobicity, solubility, purification, analytical QC and scale-up requirements for ASO, siRNA, ssDNA/dsDNA, ssRNA, probes and modified oligonucleotide constructs.

Cell Delivery Journey: Uptake → Escape → Activity
DeliveryUptakeActivity

Choose the Modification by the Uptake Problem

Instead of starting from a long product list, begin with the delivery barrier. Each strategy below connects the problem to the most practical modification class, design focus and QC consideration.

Select a delivery strategy to view recommendations

When to choose this path

Use hydrophobic or lipid-like modifications when the main limitation is weak oligo interaction with the cell surface, membrane environment or serum-binding pathway.

Recommended Modifications
Cholesterol, α-tocopherol, palmitic acid, stearic acid, oleic acid, DAG, ceramide, squalene, 2′-O-C16, 2′-O-stearyl and 2′-O-oleyl.
Best-Fit Programs
ASO, antagomir, siRNA, uptake screens, membrane-association studies and lipid-comparator panels.
Design & QC Focus
Balance uptake benefit with hydrophobicity, solubility, HPLC behavior, LC-MS compatibility and formulation handling.

When to choose this path

Use CPP or localization peptides when cellular internalization needs active enhancement or when the payload requires stronger intracellular routing.

Recommended Modifications
TAT, penetratin, R6/R8/R9, transportan, Pep-1, MPG and nuclear localization signal peptides.
Best-Fit Programs
Difficult cell lines, splice-switching oligos, ASO delivery, imaging probes and intracellular uptake screens.
Design & QC Focus
Evaluate charge, cytotoxicity, peptide density, spacer length, conjugate purity and peptide-oligo identity.

When to choose this path

Use receptor-associated ligands when the target cell type expresses a relevant uptake receptor or when a receptor-context screen is part of the program.

Recommended Modifications
Mannose, lactose, folate, vitamin B12, RGD, iRGD, Angiopep-2, transferrin receptor peptides and albumin-binding tags.
Best-Fit Programs
Immune-cell uptake, folate receptor-positive models, integrin binding, receptor-mediated internalization and targeting screens.
Design & QC Focus
Confirm receptor context, ligand density, spacer accessibility, attachment site and conjugate profile.

When to choose this path

Use escape and release chemistry when the oligo can enter cells but remains trapped, degraded or inactive before reaching its functional compartment.

Recommended Modifications
INF7, GALA, KALA, histidine-rich peptides, HA2-derived peptides, disulfide, hydrazone, ester, Val-Cit-PAB and photocleavable linkers.
Best-Fit Programs
siRNA, ASO, cytoplasmic probes, triggered release studies and intracellular functional delivery programs.
Design & QC Focus
Coordinate uptake, endosomal escape, release trigger, linker stability, spacer chemistry and final activity readout.

Cell Delivery & Uptake Modification Selector

Use the tabs to compare uptake-focused modification categories, product options, descriptions and common applications without turning the page into a long catalog.

CPP & Localization Modifications at a Glance

Best forinternalization
Common useASO • SSO • siRNA
Design focusdensity + spacer
QC focuspeptide-oligo identity
Category Product / Conjugate Description Application
CPP TAT Peptide Arginine-rich cell-penetrating peptide General cellular uptake for ASO, SSO, probe and exploratory siRNA constructs
CPP Penetratin Homeodomain-derived cell-penetrating peptide Endocytic uptake and translocation pathway studies
CPP Poly-Arginine R6 / R8 / R9 Poly-arginine CPP series High-uptake CPP comparison and cell-line screening
CPP Transportan Amphipathic cell-penetrating peptide Delivery of diverse oligonucleotide cargo formats
CPP Pep-1 Amphipathic peptide delivery sequence Cell uptake and intracellular delivery studies
CPP MPG Peptide Amphipathic peptide carrier Oligonucleotide delivery and intracellular uptake screening
Localization Nuclear Localization Signal (NLS) Nuclear localization peptide Nuclear uptake support for antisense, splice-switching and probe constructs

Design note: CPP density can affect uptake, toxicity, solubility and purification. Evaluate linker length and placement early.

Lipid, Vitamin and Nucleoside Lipidation Modifications at a Glance

Best formembrane association
Common useASO • siRNA • antagomir
Design focushydrophobicity balance
QC focuspurity + solubility
Category Product / Conjugate Description Application
Lipid Cholesterol Hydrophobic sterol Membrane association, uptake enhancement and biodistribution tuning
Vitamin α-Tocopherol Vitamin E derivative Robustness, hydrophobic interaction and delivery-tuning studies
Fatty Acid Palmitic Acid (C16) Saturated C16 fatty acid Hydrophobic anchoring and cellular uptake comparison
Fatty Acid Stearic Acid (C18) Saturated C18 fatty acid Hydrophobic anchoring and membrane interaction
Fatty Acid Oleic Acid (C18:1) Unsaturated C18:1 fatty acid Membrane interaction with altered hydrophobicity profile
Lipid Anchor Diacylglycerol (DAG) Diacylglycerol lipid anchor Membrane association and lipid-mediated uptake studies
Lipid Phosphatidylethanolamine (PE) Lipid headgroup conjugate Anchoring, membrane interaction and endosomal delivery studies
Sphingolipid Ceramide Sphingolipid modifier Endolysosomal trafficking and membrane-interaction studies
Terpenoid Squalene Highly hydrophobic terpenoid Self-assembly, particle-like behavior and hydrophobic delivery studies
Nucleoside Lipidation 2′-O-C16 (A/C/G/U) C16 lipidated adenosine, cytidine, guanosine or uridine Internal lipidated nucleoside placement for membrane interaction studies
Nucleoside Lipidation 2′-O-Stearyl (C18) C18 stearyl lipidated nucleoside modification Internal hydrophobic modification for uptake and delivery optimization
Nucleoside Lipidation 2′-O-Oleyl (C18:1) C18:1 oleyl lipidated nucleoside modification Internal unsaturated lipid modification for membrane interaction studies

Design note: Hydrophobic modifiers can improve association but may reduce solubility or complicate purification. Balance potency with manufacturability.

Glycan and Receptor-Assisted Uptake Modifications at a Glance

Best forreceptor context
Common useASO • siRNA • probes
Design focusreceptor + spacer
QC focusconjugate profile
Category Product / Conjugate Description Application
Glycan Mannose Mannose receptor ligand Macrophage, dendritic-cell and mannose-receptor uptake studies
Glycan Lactose Lectin-binding disaccharide Lectin-mediated uptake and glycan recognition studies
Ligand Folate Folate receptor ligand Folate receptor-positive cell uptake studies
Vitamin Vitamin B12 Cobalamin receptor ligand Receptor-mediated uptake and transport studies
Peptide Ligand RGD Peptide Integrin-binding peptide motif Integrin-mediated binding and uptake studies
Peptide Ligand iRGD Peptide Tumor-penetrating RGD peptide Cell penetration and tissue-penetration model studies
Peptide Ligand Angiopep-2 Receptor-targeting peptide Receptor-assisted uptake and transport studies
Peptide Ligand Transferrin Receptor Peptides Transferrin receptor-binding peptide motifs Receptor-context uptake studies
PK Modifier Albumin-Binding Tag Serum albumin interaction motif PK extension and passive targeting studies

Design note: Receptor-assisted uptake is most useful when receptor expression, attachment site and linker accessibility are considered together.

Endosomal Escape, Spacers, Linkers and Scaffolds at a Glance

Best forintracellular availability
Common useASO • siRNA • probes
Design focusrelease trigger
QC focuslinker + conjugate identity
Category Product / Conjugate Description Application
Escape Peptide INF7 HA2-derived fusogenic peptide Endosomal disruption and cytosolic release studies
Escape Peptide GALA pH-responsive amphipathic peptide Endosomal release and pH-responsive membrane interaction
Escape Peptide KALA Lysine-rich amphipathic peptide Endosomal release and membrane destabilization studies
Escape Peptide Histidine-Rich Peptides Histidine-rich buffering sequences pH-buffering and endosomal escape screening
Escape Peptide HA2-Derived Peptides Fusogenic peptide motifs Endosomal membrane disruption studies
Spacer Short PEG / TEG Spacer Hydrophilic spacer Conjugate geometry, spacing and solubility optimization
Cleavable Disulfide Linker Redox-sensitive linkage Cytosolic release in reducing intracellular environment
Cleavable Hydrazone Linker pH-sensitive linkage Endosomal or acidic-compartment release strategy
Cleavable Ester Linker Hydrolysis-sensitive linker Controlled release and stability-tuning studies
Cleavable Val-Cit-PAB Cathepsin-cleavable linker Enzyme-triggered release studies
Cleavable Photocleavable Linker Light-triggered cleavage spacer On-demand release and photocontrol workflows
Scaffold Trebler / Doubler / PAMAM Branchers and dendrimer scaffolds Valency, payload density and multivalent uptake design

Design note: Pair uptake modifiers with a release strategy when endosomal trapping limits functional activity.

Choose Uptake Modifications Around the Delivery Goal

Cell delivery and uptake modifications are most useful when selected around the biological barrier, oligo modality and assay readout.

Select an application goal to view recommended modifications

Hydrophobic and lipid-like modifiers for improving oligo-cell interaction and uptake.

Recommended Modifications
Cholesterol, α-tocopherol, palmitic acid, stearic acid, oleic acid, 2′-O-C16, 2′-O-stearyl and 2′-O-oleyl.
Typical Uses
Passive uptake, gymnotic uptake, ASO, siRNA, antagomir and membrane-association studies.
Design Focus
Balance serum interaction, membrane association, hydrophobicity, solubility and purification behavior.

Ligand-directed uptake designs when receptor context can support internalization.

Recommended Modifications
Mannose, lactose, folate, vitamin B12, RGD, iRGD, Angiopep-2 and transferrin receptor peptides.
Typical Uses
Macrophage uptake, folate-receptor studies, integrin binding, receptor-mediated internalization and targeting screens.
Design Focus
Match receptor expression, ligand density, linker length, attachment site and assay context.

Peptide-enabled cell entry and localization for oligo constructs that need stronger internalization.

Recommended Modifications
TAT, penetratin, R6/R8/R9, transportan, Pep-1, MPG and nuclear localization signal peptides.
Typical Uses
Difficult cell lines, splice-switching oligos, ASO delivery, imaging probes and intracellular uptake screens.
Design Focus
Control charge, cytotoxicity, peptide density, spacer selection and conjugate purification.

Release-focused modifications when oligos enter cells but remain endosomally trapped.

Recommended Modifications
INF7, GALA, KALA, histidine-rich peptides, HA2-derived peptides, disulfide, hydrazone, ester, Val-Cit-PAB and photocleavable linkers.
Typical Uses
siRNA, ASO, cytoplasmic probes, triggered release studies and intracellular functional delivery programs.
Design Focus
Coordinate uptake, endosomal escape, release trigger, linker stability and final activity readout.

Compare Uptake Support, Solubility and Complexity

Use this table as a practical screening guide. Actual performance depends on sequence, chemistry pattern, cell type, linker, conjugation site, formulation and assay readout.

Cell Delivery Modification Comparison

Ratings are qualitative design guides for selecting a starting point.

Modification Class Uptake Support Solubility Impact Complexity Best-Fit Use
Cell-Penetrating Peptides ★★★★★ Medium ★★★★ Internalization screens, ASO/SSO delivery and peptide-mediated uptake.
Cholesterol / Lipids ★★★★★ High ★★ Membrane association, uptake enhancement and biodistribution tuning.
Nucleoside Lipidations ★★★★ Medium-High ★★★★ Advanced RNA/ASO constructs where internal lipid placement is useful.
Glycan / Receptor Ligands ★★★ Low-Medium ★★★★ Cell-type or receptor-context uptake studies.
Endosomal Escape Peptides ★★★★ Medium ★★★★★ Improving intracellular availability after uptake.
Cleavable Linkers ★★ Low ★★★★ Payload release, cytosolic release or triggered activity designs.

Workflow for Cell Uptake-Modified Oligos

A successful cell delivery modification program connects uptake biology with conjugation design, oligo synthesis, purification and analytical release.

01
Barrier Definition

Define uptake, trafficking, endosomal release or localization challenge.

02
Modifier Selection

Select CPP, lipid, glycan, ligand, spacer or cleavable linker.

03
Oligo Build

Synthesize DNA, RNA, ASO, siRNA or probe with compatible handle.

04
Conjugation

Attach modifier using selected chemistry, spacer and orientation.

05
Purification

Use HPLC/UPLC, desalting or method-matched cleanup.

06
QC & Delivery

Release with purity, identity, concentration, CoA and packaging.

QC Strategy for Delivery-Modified Oligos

Bio-Synthesis supports analytical characterization strategies for cell uptake-modified oligonucleotides using methods that evaluate purity, identity, conjugate profile, solubility, concentration and release-critical attributes.

Analytical Control Matrix

Hydrophobic and peptide-conjugated oligos may require method-matched purification and QC because cellular uptake modifiers can change chromatographic behavior, solubility and mass confirmation strategy.

HPLC / UPLC

Purity assessment and chromatographic profile for modified oligos.

LC-MS

Mass identity confirmation where compatible with construct size and chemistry.

OD260 / Concentration

Quantitation, normalization and formulation-ready concentration reporting.

Custom QC

Optional endotoxin, residuals, solubility, stability and plate formatting.

Hydrophobicity Review

Plan purification and handling around lipid load and solubility.

Conjugate Identity

Confirm modified oligo profile and attachment where method-compatible.

Scale & Packaging

µmol screens to larger supply, tubes, vials, plates, labels and barcodes.

Purity
Identity
Solubility
Concentration
Documentation

Quality Support for Uptake-Modified Oligos

Cell delivery-modified oligonucleotides require controlled synthesis, conjugation, purification and analytical release methods matched to the modifier and application.

QMS

ISO-Supported Cell Delivery Oligo Platform

Bio-Synthesis supports design, synthesis, conjugation, purification, analytical characterization and documentation for uptake-enabled oligonucleotide programs.

ISO 9001:2015 Quality management system
ISO 13485:2016 Medical-device quality framework
Analytical QC HPLC/UPLC, LC-MS, OD260 and CoA
Custom Programs CPP, lipid, glycan, linker and scaffold support

FAQ

Which approach should I try first, CPPs or lipids?
For early screening, compare cholesterol or a short CPP such as TAT, R9 or penetratin with a PEG/TEG spacer. Choose based on oligo modality, cell type, toxicity, solubility and assay readout.
Where should the conjugate be placed on siRNA or ASO?
Terminal placement is common. For siRNA, sense-strand 3′ placement is often evaluated to preserve guide-strand activity. For ASO, 3′ placement can reduce steric interference, but activity should be validated experimentally.
How do I improve endosomal release?
Evaluate fusogenic or pH-responsive peptides such as INF7, GALA or KALA/Hn, and consider cleavable linkers such as disulfide, Val-Cit-PAB or hydrazone for intracellular availability.
Do lipid modifications affect purification?
Yes. Cholesterol, fatty acids, DAG, ceramide and lipidated nucleosides can change solubility and chromatographic behavior. Purification and handling should be reviewed early.
Can Bio-Synthesis supply plate-based screening panels?
Yes. Tubes, vials and plate formats with labels, barcodes, concentration normalization and CoA documentation can be supported for screening workflows.
What information is needed for a quote?
 Provide sequence, modality, desired modifier, conjugation position, linker preference, scale, purification, QC requirements, format and application details.

Information Helpful for Uptake-Modified Oligos

Modality
ASO, siRNA, DNA, RNA
Sequence
5′→3′ and chemistry pattern
Modifier
CPP, lipid, glycan, linker
Placement
5′, 3′, internal, branch
Scale
nmol, µmol, mg, gram
QC
HPLC, LC-MS, CoA

Need help designing a cell uptake-modified oligo?

Share your oligo sequence, modality, cell type, desired uptake modifier, conjugation position, linker strategy, scale, purification and QC requirements. Bio-Synthesis can help evaluate manufacturability and build a delivery-ready workflow around your program.
Up

Uptake Strategy Review

Compare CPP, lipid, glycan, receptor-assisted and endosomal escape approaches.

CPP Lipid Glycan Escape
QC

Conjugate Package

Purification, LC-MS, analytical purity, conjugate confirmation, labeling and documentation.

HPLC LC-MS CoA Custom QC

Recommended Reading & Literature References

Use this section to support scientific credibility while keeping the page focused on cell uptake modification strategy, synthesis and analytical verification.

  1. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Research. 2016;44(14):6518–6548.
  2. Crooke ST, Wang S, Vickers TA, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. Nature Biotechnology. 2017;35:230–237.
  3. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery. 2020;19:673–694.
  4. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnology. 2007;25:1149–1157.
  5. Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Therapeutics. 2018.

Suggested page note: Literature references are provided for scientific background. Final uptake-modified oligonucleotide design should be evaluated within the sequence, modality, modifier, linker, purification method, analytical QC and application model.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.